Orthopedic device company RTI Surgical partnered with Exactech to develop and supply biologic bone grafts.
Under the agreement, RTI Surgical acquired Exactech's Optecure, a demineralized bone matrix intended for use as a bone graft extender in the spine, pelvis and extremities.
This is RTI Surgical's first acquisition since its original equipment manufacturer business was sold to Montagu Private Equity in a $480 million deal in July 2020. The OEM business develops biologic, metal and synthetic implants for spine, orthopedics, sports medicine and trauma, among other specialties.
"This collaboration with RTI allows each company to focus on our unique strengths," Exactech CEO Darin Johnson said in a July 13 news release. "RTI has specialized expertise in the procurement, processing and manufacturing of human-derived tissue-based implants and Exactech markets and distributes the clinical solutions to help surgeons treat patients."